Antiangiogenic therapies: going beyond their limits

Lidia Moserle1, Gabriela Jiménez-Valerio, Oriol Casanovas

  • 1Tumor Angiogenesis Group, Catalan Institute of Oncology-IDIBELL, Av Gran Via de l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.

Cancer Discovery
|December 21, 2013
PubMed

Insights

Antiangiogenic therapies slow tumor growth but have limitations. New strategies and biomarkers are needed to improve treatment efficacy and benefit more cancer patients.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Tumor growth depends on angiogenesis, the formation of new blood vessels.
  • Antiangiogenic drugs target this process to inhibit tumor progression.

Purpose of the Study:

  • To review the limitations of current antiangiogenic therapies.
  • To discuss mechanisms, controversies, and emerging strategies to overcome these limitations.

Main Methods:

  • Literature review of antiangiogenic therapy limitations.
  • Analysis of predictive biomarkers and therapeutic strategies.

Main Results:

  • Antiangiogenic therapies show limited clinical benefit despite reducing angiogenesis.
  • Existing therapies face challenges due to inherent limitations and resistance mechanisms.

Conclusions:

  • Predictive biomarkers and novel treatment strategies are crucial for enhancing antiangiogenic therapy efficacy.
  • Overcoming current limitations will lead to improved and durable responses in a broader patient population.

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K